An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 10, 2013, Pages 1333-1344

  Bruzziches, Roberto ^a   Francomano, Davide ^a   Gareri, Pietro ^b   Lenzi, Andrea ^a   Aversa, Antonio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ASP Catanzaro   (Italy)

Author keywords

Avanafil; Efficacy; Geriatric; Mirodenafil; Safety; Sildenafil; Tadalafil; Udenafil; Vardenafil

Indexed keywords

AVANAFIL; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; LODENAFIL; MIRODENAFIL; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; UDENAFIL; VARDENAFIL;

ABNORMAL VISION; ANTERIOR ISCHEMIC OPTIC NEUROPATHY; AREA UNDER THE CURVE; BACKACHE; COMPARATIVE EFFECTIVENESS; DIABETIC CARDIOMYOPATHY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TRANSFORMATION; DYSPEPSIA; ENZYME THERAPY; ERECTILE DYSFUNCTION; FIRST PASS EFFECT; FLUSHING; HEADACHE; HEARING IMPAIRMENT; HUMAN; HYPOTENSION; IN VITRO STUDY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NOSE OBSTRUCTION; PRACTICE GUIDELINE; PREMATURE EJACULATION; PRIAPISM; REVIEW; RHINITIS; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

AGED; ERECTILE DYSFUNCTION; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS; TREATMENT OUTCOME;

EID: 84878875071     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.799665     Document Type: Review

References (92)

1. Hatzimouratidis K, Amar E, Eardley I, et al. European association of urology. guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010;57:804-14
2. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral Sildenafil in the treatment of erectile dysfunction. Sildenafil study group. N Engl J Med 1998;338:1397-404
3. Bell AS, Palmer MJ. Novel phosphodiesterase type 5 modulators: 481 a patent survey (2008-2010). Expert Opin Ther Pat 2011;21:482 1631-41
4. Aversa A, Bruzziches R, Pili M, et al. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Des 2006;12:3467-84
5. Hatzichristou D, Rosen RC, Broderick G, et al. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med 2004;1:4957
6. Aversa A, Bruzziches R, Francomano D, et al. Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine? Ther Adv Urol 2009;1:179-97
7. Hatzimouratidis K. Non-responders to phosphodiesterase type 5 inhibitors: is there a second chance? J Men's Health Gender 2006;3:342-9
8. McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ 2006;332:589-92
9. Son H, Park K, Kim SW, et al. Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J Androl 2004;6:117-20
10. Hackett GI. Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. Clin Cornerstone 2005;7:57-65
11. Aversa A, Jannini EA, Maggi M, Lenzi A. Effects of testosterone replacement on response to sildenafil citrate. Ann Intern Med 2013;158:569-70
12. Aversa A. Drugs targeted to improve endothelial function: clinical correlates between sexual and internal medicine. Curr Pharm Des 2008;14:3698-9
13. Aversa A, Caprio M, Rosano GM, et al. Endothelial effects of drugs designed to treat erectile dysfunction. Curr Pharm Des 2008;14:3768-78
14. McMahon CG. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 2004;1:292-300
15. Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo controlled trial. Eur Urol 2006;50:351-9
16. McMahon CG. Comparison, efficacy, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005;2:415-25
17. Rosano GM, Aversa A, Vitale C, et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005;47:214-22
18. Porst H, Brock GB, Kula K, et al. Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors. J Androl 2012;33:1305-22
19. Shindel AW. 2009 Update on phosphodiesterase type 5 inhibitor therapy Part 1: recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications. J Sex Med 2009;6:1794-808
20. Giannetta E, Isidori AM, Galea N, et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 2012;125(19):2323-33
21. Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012;61:917-25
22. Francis SH, Busch JL, Corbin JD, et al. CGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 2010;62:525-63
23. Behr-Roussel D, Gorny D, Mevel K, et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 2005;47:87-91
24. Aversa A, Bruzziches R, Vitale C, et al. Chronic sildenafil in men with diabetes and erectile dysfunction. Expert Opin Drug Metab Toxicol 2007;3:451-64
25. Kanwar M, Agarwal R, Barnes M, et al. Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts. Curr Heart Fail Rep 2013;10:26-35
26. Tignol J, Furlan PM, Gomez-Beneyto M, et al. Efficacy of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in 585 remission from depression. Int Clin Psychopharmacol 2004;19:191-9
27. Rosato E, Letizia C, Proietti M, et al. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis. J Biol Regul Homeost Agents 2009;23:23-9
28. Safarinejad MR. Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: a 593 double-blind, placebo controlled, randomized study. J Urol 2009;181:252-8
29. Basu A, Ryder RE. New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs 2004;64:2667-88
30. Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract 2006;60:967-75
31. Fabbri A, Aversa A, Isidori A. Sildenafil and erectile dysfunction. J Endocrinol Invest 1999;22(6):486-92
32. Morales A, Gingell C, Collins M, et al. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 1998;10(2):69-73
33. Aversa A, Bruzziches R, Vitale C, et al. Chronic sildenafil in men with diabetes and erectile dysfunction. Expert Opin Drug Metab Toxicol 2007;3:451-64
34. Padma-Nathan H. Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. Am J Cardiol 2003;92(9A):19M-25M
35. Porst H, Padma-Nathan H, Giuliano F, et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003;62:121-6
36. Shabsigh R, Eardley I, Whitaker S, et al. Time distribution of sexual intercourse attempts after taking tadalafil or placebo. Int J Impot Res 2003;15(suppl 5):S177
37. Montorsi F, Verheyden B, Meuleman E, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004;45:339-44
38. Weeks JL II, Zoraghi R, Beasley A, et al. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. Int J Impot Res 2005;17:5-9
39. Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003;42:1855-60
40. Bruzziches R, Greco EA, Pili M, et al. Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction. Curr Diabetes Rev 2008;4:24-30
41. Giuliano F, Oelke M, Jungwirth A, et al. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo-and tamsulosin-controlled, 12-week double-blind study. J Sex Med 2013;doi: 10.1111/jsm.12039; [Epub ahead of print]
42. Bischoff E. Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int J Impot Res 2004(16 Suppl 1):34-7
43. Hellstrom WJ. Vardenafil. a new approach to the treatment of erectile dysfunction. Curr Urolol Rep 2003;4:479-87
44. Goldstein I, Young JM, Fischer J, et al. Vardenafil Diabetes Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83
45. Brock G, Nehra A, Lipshultz LI, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. Urology 2003;170(4 Pt 1):1278-83
46. Jannini EA, McMahon C, Chen J, et al. The controversial role of phosphodiesterase type 5 inhibitors in the treatment of premature ejaculation. J Sex Med 2011;8:2135-43
47. Heinig R, Weimann B, Dietrich H, et al. Pharmacokinetics of a new orodispersible table formulation of vardenafil: results of three clinical trials. Clin Drug Invest 2011;31:27-41
48. Sanford M. Vardenafil orodispersible tablet. Drugs 2012;72:87-98
49. Sperling H, Debruyne F, Boermans A, et al. The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. J Sex Med 2010;7(4 Pt 1):1497-507
50. Gittelman M, McMahon CG, Rodriguez-Rivera JA, et al. The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Int J Clin Pract 2010;64:594-603
51. Salem EA, Kendirci M, Hellstrom WJ. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Investig Drugs 2006;7:661-9
52. Ding H, Du W, Wang H, et al. Efficacy and safety of udenafil for erectile dysfunction: a metaanalysis of randomized controlled trials. Urology 2012;80:134-9
53. US Food and Drug Administration. FDA approves Stendra for erectile dysfunction. Available from: http://www. fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm302140.htm [Accessed 1 May2012]
54. Alwaal A, Al-Mannie R, Carrier S. Future prospects in the treatment of erectile dysfunction: focus on avanafil. Drug Des Dev Ther 2011;5:435-43
55. Burke RM, Evans JD. Avanafil for treatment of erectile dysfunction: review of its potential. Vasc Health Risk Manag 2012;8:517-23
56. Kim BH, Yi S, Kim J, et al. Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomizedsequence, open-label, crossover study in healthy male volunteers in Korea. Clin Ther 2009;31:1234
57. Shin HI, Lee J, Kim DK. Synthesis of 5-ethyl-2-{5-[4-(2-hydroxyethyl) piperazin-1-ylsulfonyl]-2-npropoxyphenyl}-7-npropyl-3,5-dihydro-4Hpyrrolo[3,2-d] -[2-14C]pyrimidin-4-one2HCl (14CSK3530. 2 HCl). J Labelled Comp Radiopharm 2006;49:1141-9
58. Lee J, Yoo HH, Rhim KJ, et al. Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl) piperazine-1-sulfonyl]-2-propoxyphenyl}-7- propyl-3,5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK 3530) in rats. Rapid Commun Mass Spectrom 2007;21:1139-49
59. Paick JS, Choi HK, Kim SC, et al. Efficacy and safety of oral SK3530 in the treatment of men in Korea with erectile dysfunction: a multicentre, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial. J Sex Med 2006;3(5 suppl):393
60. Paick JS, Ahn TY, Choi HK, et al. Efficacy and safety of mirodenafil, a new oral Phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008;5:2672
61. Jannini EA, Isidori AM, Gravina GL, et al. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. J Sex Med 2009;6:2547-60
62. Rubio-Aurioles E, Porst H, Kim ED, et al. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med 2012;9:1418-29
63. Buvat J, Buttner H, Hatzimouratidis K, et al. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. J Sex Med 2013; Epub ahead of print
64. Yoo C, Park J, Kim W, et al. Comparison of the efficacy, safety and patient preference of the phosphodiesterase type 5 inhibitors for the patients with erectile dysfunction. Korean J Urol 2007;48:219-25
65. Govier F, Potempa AJ, Kaufman J, et al. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther 2003;25:2709-23
66. Moore R, Derry S, McQuay H. Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction. BMC Urol 2005;5:18
67. Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 2009;151:650-61
68. Canadian Agency for Drugs and Technologies in Health. Phosphodiesterase 5 inhibitors: a review of the clinical effectiveness and cost-effectiveness. In: CAfDaTi, editor. Health. Ottawa: 2010
69. Yuan J, Zhang R, Yang Z, et al. The comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: 5 a systematic review and network meta-analysis. Eur Urol 2013; doi: 10.1016/j.eururo.2013.01.012; [Epub ahead of print]
70. Ljunggren C, Hedelin H, Salomonsson K, et al. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. J Sex Med 2008;5:469-75
71. Klotz T, Mathers M, Klotz R, et al. Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra)? Int J Impot Res 2005;17:2-4
72. Son H, Park K, Kim SC, et al. Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J Androl 2004;6:117-20
73. Jiann B, Yu C, Su C, et al. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res 2006;18:146-9
74. Salonia A, Gallina A, Zanni G, et al. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nervesparing radical prostatectomy. Eur Urol 2008;53:564-70
75. Carvalheira AA, Pereira NM, Maroco J, et al. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. J Sex Med 2012;9:2361-9
76. Corona G, Mondaini N, Ungar A, et al. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: The proper drug for the proper patient. J Sex Med 2011;8:3418-32
77. Jannini EA, DeRogatis LR, Chung E, Brock GB. How to evaluate the efficacy of PDE5 inhibitors. J Sex Med 2012;9:26-33
78. Wespes E, Amar E, Hatzichristou D, et al. EAU Guidelines on erectile dysfunction: an update. Eur Urol 2006;49:806-15
79. Shiri R, Koskimaki J, Hakkinen J, et al. Tampere Ageing Male Urological Study. Effects of age, comorbidity and lifestyle factors on erectile function: tampere Ageing Male Urological Study (TAMUS). Eur Urol 2004;45:628-33
80. Sharlip ID, Shumaker BP, Hakim LS, et al. Tadalafil is efficacious and well tolerated in the treatment of erectile dysfunction (ED) in men over 65 years of age: results from Multiple Observations in Men with ED in National Tadalafil Study in the United States. J Sex Med 2008;5:716-25
81. Francomano D, Bruzziches R, Natali M, et al. Cardiovascular effect of testosterone replacement therapy in aging male. Acta Biomed 2010;81:Suppl 1:101-6
82. McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ 2006;332:589-92
83. Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs 2005;65:1621-50
84. Andersson KE, de Groat WC, McVary KT, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011;30:292-301
85. El-Sakka AI. Alleviation of post-radical prostatectomy cavernosal fibrosis: future directions and potential utility for PDE5 inhibitors. Expert Opin Investig Drugs 2011;20:1305-9
86. Aversa A, Bruzziches R, Francomano D, et al. Endothelial dysfunction and erectile dysfunction in the aging man. Int J Urol 2010;17:38-47
87. Nehra A, Jackson J, Miner M, et al. The Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012;87:766-78
88. Shon JH, Ku HY, Bae SY, et al. The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. Pharmacogenet Genomics 2011;21:820-8
89. Borer J, Armstrong P. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee; May 29th and 30th, 2003; Circulation 2003. 107: e9052
90. Porst H, Brock GB, Kula K, et al. Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors. J Androl 2012;33:1305-22
91. Aversa A, Pili M, Francomano D, et al. Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. Int J Impot Res 2009;21:221-7
92. Francomano D, Donini LM, Lenzi A, Aversa A. Peripheral arterial tonometry to measure the effects of Vardenafil on sympathetic tone in men with lifelong premature ejaculation. Int J Endocrinol, 2013.2013, Article ID 394934, 9 pages. Available from: http://dx.doi.org/10.1155/2013/394934